Drugs / MRX-1024
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00427102 | Jan → Jul 2007 | head and neck cancer, mucositis, squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRX-1024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00427102 ↗ |
| Route | Oral | “MRX 1024 doses of 100 mgkg given orally twice a day, five days a week during radiation treatment cycles” NCT00427102 ↗ |